News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
41.12 ^USD	+2.17%		-0.28%	-19.85%

May. 30	Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	MT
May. 30	Bristol Myers: FDA approval for Breyanzi	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	May. 30	MT
Bristol Myers: FDA approval for Breyanzi	May. 30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	May. 30	RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	May. 30	BU
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	May. 30	CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval	May. 29	MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer	May. 29	MT
Bristol Myers: new EC approval for Opdivo	May. 29	CF
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	May. 29	BU
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine	May. 29	CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	May. 28	MT
Bristol Myers: will present data on schizophrenia	May. 27	CF
Bristol Myers: presents over 130 studies at ASCO	May. 27	CF
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms	May. 23	BU
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	May. 23	MT
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	May. 23	BU
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	May. 22	RE
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab	May. 22	AQ
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	May. 22	MT
Bristol Myers: 10-year strategy for poor countries	May. 22	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST